These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 25547438)

  • 1. "Long-acting" olanzapine in maintenance therapy of schizophrenia: A study with plasma levels.
    Mauri MC; Maffini M; Di Pace C; Reggiori A; Paletta S; Moliterno D; Rovera C; Altamura CA
    Int J Psychiatry Clin Pract; 2015 Jun; 19(2):99-105. PubMed ID: 25547438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single- and multiple-dose pharmacokinetic, safety, and tolerability profiles of olanzapine long-acting injection: an open-label, multicenter, nonrandomized study in patients with schizophrenia.
    Mitchell M; Kothare P; Bergstrom R; Zhao F; Jen KY; Walker D; Johnson J; McDonnell D
    Clin Ther; 2013 Dec; 35(12):1890-908. PubMed ID: 24184052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcome and olanzapine plasma levels in acute schizophrenia.
    Mauri MC; Steinhilber CP; Marino R; Invernizzi E; Fiorentini A; Cerveri G; Baldi ML; Barale F
    Eur Psychiatry; 2005 Jan; 20(1):55-60. PubMed ID: 15642445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia.
    Kane JM; Detke HC; Naber D; Sethuraman G; Lin DY; Bergstrom RF; McDonnell D
    Am J Psychiatry; 2010 Feb; 167(2):181-9. PubMed ID: 20008947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of Plasma Levels of Olanzapine and N-Desmethyl-Olanzapine to Monitor Clinical Efficacy in Patients with Schizophrenia.
    Lu ML; Wu YX; Chen CH; Kuo PT; Chen YH; Lin CH; Wu TH
    PLoS One; 2016; 11(2):e0148539. PubMed ID: 26849777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of olanzapine long-acting injection and oral olanzapine: a 2-year, randomized, open-label study in outpatients with schizophrenia.
    Detke HC; Weiden PJ; Llorca PM; Choukour M; Watson SB; Brunner E; Ascher-Svanum H
    J Clin Psychopharmacol; 2014 Aug; 34(4):426-34. PubMed ID: 24781441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of olanzapine long-acting injection in patients with acutely exacerbated schizophrenia: an insight from effect size comparison with historical oral data.
    Detke HC; Zhao F; Witte MM
    BMC Psychiatry; 2012 May; 12():51. PubMed ID: 22646847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Baseline characteristics and hospitalizations in patients with schizophrenia receiving olanzapine long-acting injection: an interim analysis from a non-interventional, prospective observational safety study.
    Jones ME; Andrews JS; Faries DE; Landry J; Xu J; Detke HC; Chhabra-Khanna R; McDonnell DP
    BMC Psychiatry; 2015 Nov; 15():278. PubMed ID: 26567159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term safety and efficacy of olanzapine long-acting injection in patients with schizophrenia or schizoaffective disorder: a 6-year, multinational, single-arm, open-label study.
    McDonnell DP; Landry J; Detke HC
    Int Clin Psychopharmacol; 2014 Nov; 29(6):322-31. PubMed ID: 24850228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-dependent effects of olanzapine on QT intervals and plasma prolactin levels in Japanese patients with stable schizophrenia.
    Suzuki Y; Ono S; Sugai T; Fukui N; Watanabe J; Tsuneyama N; Sawamura K; Someya T
    Hum Psychopharmacol; 2011 Aug; 26(6):440-3. PubMed ID: 21823168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidences of extrapyramidal symptoms in patients with schizophrenia after treatment with long-acting injection (depot) or oral formulations of olanzapine.
    Hill AL; Sun B; McDonnell DP
    Clin Schizophr Relat Psychoses; 2014 Jan; 7(4):216-22. PubMed ID: 23428782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of metabolic changes in patients with schizophrenia during randomized treatment with intramuscular olanzapine long-acting injection versus oral olanzapine.
    McDonnell DP; Kryzhanovskaya LA; Zhao F; Detke HC; Feldman PD
    Hum Psychopharmacol; 2011 Aug; 26(6):422-33. PubMed ID: 21823172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases.
    Detke HC; McDonnell DP; Brunner E; Zhao F; Sorsaburu S; Stefaniak VJ; Corya SA
    BMC Psychiatry; 2010 Jun; 10():43. PubMed ID: 20537128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of olanzapine long-acting injection on levels of functioning among acutely ill patients with schizophrenia.
    Witte MM; Case MG; Schuh KJ; Ascher-Svanum H
    Curr Med Res Opin; 2012 Mar; 28(3):315-23. PubMed ID: 22236137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pooled analysis of injection site-related adverse events in patients with schizophrenia treated with olanzapine long-acting injection.
    Atkins S; Detke HC; McDonnell DP; Case MG; Wang S
    BMC Psychiatry; 2014 Jan; 14():7. PubMed ID: 24423017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia.
    Lauriello J; Lambert T; Andersen S; Lin D; Taylor CC; McDonnell D
    J Clin Psychiatry; 2008 May; 69(5):790-9. PubMed ID: 18452346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of plasma levels of olanzapine and N-desmethyl-olanzapine to monitor metabolic parameters in patients with schizophrenia.
    Lu ML; Chen CH; Kuo PT; Lin CH; Wu TH
    Schizophr Res; 2018 Mar; 193():139-145. PubMed ID: 28720417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LAI versus oral: A case-control study on subjective experience of antipsychotic maintenance treatment.
    Pietrini F; Spadafora M; Tatini L; Talamba GA; Andrisano C; Boncompagni G; Manetti M; Ricca V; Ballerini A
    Eur Psychiatry; 2016 Sep; 37():35-42. PubMed ID: 27442981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A single-blind, randomized comparison of olanzapine at a starting dose of 5 mg versus 20 mg in acute schizophrenia.
    Mauri MC; Colasanti A; Rossattini M; Moliterno D; Baldi ML; Papa P
    Clin Neuropharmacol; 2006; 29(3):126-31. PubMed ID: 16772810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Olanzapine pamoate for the treatment of schizophrenia.
    Naber D
    Expert Opin Pharmacother; 2011 Mar; 12(4):627-33. PubMed ID: 21254860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.